Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

Child and Adolescent Psychiatry and Mental Health

Volumn 4, Issue , 2010, Pages

  Wehmeier, Peter M ^a,b   Schacht, Alexander ^a   Escobar, Rodrigo ^c   Savill, Nicola ^d   Harpin, Val ^e  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ELI LILLY AND COMPANY   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

AGE SPECIFIC CARE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD HEALTH; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHOOL CHILD; SYMPTOM; TREATMENT RESPONSE;

EID: 78649692877     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-4-30     Document Type: Article

References (49)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164(6):942-948. 10.1176/appi.ajp.164.6.942, 17541055.
2. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 2006, 67(4):524-540. 10.4088/JCP.v67n0403, 16669717.
3. Brassett-Harknett A, Butler N. Attention-deficit/hyperactivity disorder: an overview of the etiology and a review of the literature relating to the correlates and lifecourse outcomes for men and women. Clin Psychol Rev 2007, 27(2):188-210. 10.1016/j.cpr.2005.06.001, 16081194.
4. Escobar R, Hervas A, Soutullo CA, Mardomingo MJ, Uruñuela A, Gilaberte I. Attention-deficit/hyperactivity disorder: burdens of the disease according to subtypes in recently diagnosed children. Actas Esp Psiquiatr 2008, 36(5):285-294.
5. Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health 2010, 46:209-217. 10.1016/j.jadohealth.2009.09.009, 20159496.
6. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, Santosh P, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Zuddas A, Coghill D. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010, 19(2):83-105. 10.1007/s00787-009-0046-3, 19633992.
7. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005, 90(1):i2-i7. 10.1136/adc.2004.059006, 1765272, 15665153.
8. Riley AW, Spiel G, Coghill D, Döpfner M, Falissard B, Lorenzo MJ, Preuss U, Ralston SJ, . ADORE Study Group Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 2006, 15(Suppl1):138-145. ADORE Study Group.
9. Hakkaart-van Roijen L, Zwirs BWC, Bouwmans C, Tan SS, Schulpen TW, Vlasveld L, Buitelaar JK. Societal cost and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007, 16(5):316-326. 10.1007/s00787-007-0603-6, 17483870.
10. Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q 2008, 79(2):133-137. 10.1007/s11126-008-9070-6, 18327640.
11. Wallander JL, Schmitt M, Koot HM. Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol 2001, 57(4):571-585. 10.1002/jclp.1029, 11255207.
12. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007, 194(2):197-209. 10.1007/s00213-007-0840-x, 17572882.
13. Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB, Elliott G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K, Wigal T. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Dev Behav Pediatr 2001, 22(1):60-73.
14. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004, 114(1):e1-8. 10.1542/peds.114.1.e1, 15231966.
15. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, . Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108(5):E83. 10.1542/peds.108.5.e83, 11694667, Atomoxetine ADHD Study Group.
16. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002, 159(11):1896-1901. 10.1176/appi.ajp.159.11.1896, 12411225.
17. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63(12):1140-1147.
18. Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D, . Atomoxetine International Study Group A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004, 13(4):249-257. 10.1007/s00787-004-0401-3, 15365896, Atomoxetine International Study Group.
19. Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 2004, 25(4):264-271. 10.1097/00004703-200408000-00006, 15308927.
20. Perwien AR, Kratochvil CJ, Faries DE, Vaughan BS, Spencer T, Brown RT. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?. J Child Adolesc Psychopharmacol 2006, 16(6):713-724. 10.1089/cap.2006.16.713, 17201615.
21. Matza LS, Stoeckl MN, Shorr JM, Johnston JA. Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Rev Pharmacoeconomics Outcomes Res 2006, 6(4):379-390.
22. Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) 2006, 45(9):819-827. 10.1177/0009922806294219, 17041169.
23. Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, . Puvanendran on behalf of the SUNBEAM Study Group A multicentre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007, 23(2):379-394. 10.1185/030079906X167309, 17288692, Puvanendran on behalf of the SUNBEAM Study Group.
24. Wehmeier PM, Dittmann RW, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents and physicians in an open-label study. J Child Adolesc Psychopharmacol 2007, 17:813-830. 10.1089/cap.2007.0025, 18315453.
25. Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS. Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). Child Adolesc Psychiatry Ment Health 2008, 2(1):11. 10.1186/1753-2000-2-11, 2430545, 18507848.
26. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002, 111(2):279-289. 10.1037/0021-843X.111.2.279, 12003449.
27. Fayyad J, De Graaf R, Kessler RC, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C, Lépine JP, Ormel J, Posada-Villa J, Zaslavsky AM, Jin R. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007, 190(5):402-409. 10.1192/bjp.bp.106.034389, 17470954.
28. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug and Alcohol Dependence 2008, 95:140-146. 10.1016/j.drugalcdep.2008.01.008, 18328639.
29. Wolraich ML, Wibbelsman CJ, Brown TE, Evans SW, Gotlieb EM, Knight JR, Ross EC, Schubiner HH, Wender EH, Wilens T. Attention-Deficit/Hyperactivity Disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005, 115(6):1734-1746. 10.1542/peds.2004-1959, 15930238.
30. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63(12):10-15.
31. Murphy K, Barkley RA. Prevalence of DSM-IV Symptoms of ADHD in adult licensed drivers: Implication for clinical diagnosis. J Atten Disord 1996, 1(3):147-161.
32. Kordon A, Kahl KG, Wahl K. A new understanding of attention-deficit disorders--beyond the age-at-onset criterion of DSM-IV. Eur Arch Psyhiatry Clin Neurosci 2006, 256(1):i47-54.
33. Riley AW, Robertson J, Forrest CB, Green B, Rebok G, Starfield B. Manual for the Child Health and Illness Profile-Child Edition (CHIP-CETM) 2001, Baltimore, MD: The Johns Hopkins University.
34. Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care 2004, 42(3):210-220. 10.1097/01.mlr.0000114909.33878.ca, 15076820.
35. Riley AW, Chan KS, Prasad S, Poole L. A global measure of child health-related quality of life: reliability and validity of the Child Health and Illness Profile - Child Edition (CHIP-CE) global score. J Med Economics 2007, 10(2):91-106.
36. Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Poole L, Kadesjö B. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind placebo controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009, 18(4):240-249. 10.1007/s00787-008-0725-5, 19156355.
37. Escobar R, Montoya A, Polavieja P, Cardo E, Artigas J, Hervas A, Fuentes J. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention- deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(3):253-263. 10.1089/cap.2008.0109, 19519260.
38. Dell'Agnello G, Maschiatto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, . LYCY Study Group Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. Eur Neuropsychopharmacol 2009, 19(11):822-834. LYCY Study Group.
39. Dickson RA, Jackiewicz G, Khattak S, et al. Change in ADHD symtoms and functional outcomes in Canadian Children during 3 Months of atomoxetine treatment. Poster presented at the 27th Annual Conference of the Canadian Academy of Child and Adolescent Psychiatry (CACAP) 2007, Montreal, Quebec.
40. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR) 2000, Washington, DC: American Psychiatric Association, Fourth, American Psychiatric Association.
41. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: checklists, norms, and clinical interpretations 1998, New York: Guilford.
42. Swanson J. School-Based Assessment and Interventions for ADD 1992, 184. KC Publishing, Irvine.
43. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36(7):980-989. 10.1097/00004583-199707000-00021, 9204677.
44. Guy W, . ed ECDEU assessment manual for psychopharmacology: publication ADM 76-338 1996, 218-222. Washington, DC: US Department of Health, Education and Welfare, ed.
45. Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J, . ADHD European Guidelines Group Practitioner review: quality of life in child mental health - conceptual challenges and practical choices. J Child Psychol Psychiatry 2009, 50(5):544-561. 10.1111/j.1469-7610.2009.02008.x, 19432681, ADHD European Guidelines Group.
46. Goodman D, Faraone SV, Adler LA, Dirks B, Hamdani M, Weisler R. Interpreting ADHD Rating Scale Scores: Linking ADHD Rating Scale Scores and CGI Levels in Two Randomized Controlled Trials of Lisdexamfetamine Dimesylate in ADHD. Primary Psychiatry 2010, 17(3):44-52.
47. Steinhausen HC, Nøvick TS, Baldursson G, Curatolo P, Lorenzo MJ, Rodrigues Pereira R, Ralston SJ, Rothenberger A, . ADORE Study Group Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006, 15(Suppl. 1):125-129. ADORE Study Group.
48. Escobar R, Schacht A, Wehmeier PM, Wagner T. Quality of life and ADHD core symptoms: A pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol 2010, 30(2):145-151. 10.1097/JCP.0b013e3181d21763, 20520287.
49. Riley AW, Green BF, Forrest CB, Starfield B, Kang M, Ensminger ME. A taxonomy of adolescent health: development of the adolescent health profile-types. Medical Care 1998, 36(8):1228-1236. 10.1097/00005650-199808000-00010, 9708594.